Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 5/20 | 0.47 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 6/20 | 0.41 |
| ▸ | RAB9A | P51151 | 6/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | NR0B1 | P51843 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | CGAS | Q8N884 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8166679 | 0.84 | FDPS (0.62) | FDPSNPC1RAB9APOLBTSHR | |
| SCHEMBL7784728 | 0.80 | NPC1 (0.49) | FDPSNPC1RAB9A | |
| SCHEMBL7790447 | 0.77 | FDPS (0.69) | FDPSNPC1RAB9ANR0B1 | |
| SCHEMBL7793553 | 0.77 | GRM5 (0.50) | — | |
| SCHEMBL5360999 | 0.75 | FDPS (0.58) | FDPSPOLBHTT | |
| SCHEMBL7790467 | 0.75 | POLB (0.40) | NPC1RAB9APOLBHTT | |
| SCHEMBL8165471 | 0.74 | FDPS (0.68) | FDPSNPC1RAB9AATMTSHR | |
| SCHEMBL5366533 | 0.71 | FDPS (0.59) | FDPSNPC1RAB9APOLBTSHR | |
| SCHEMBL7793634 | 0.70 | FDFT1 (0.42) | PTPN2PTPN1POLB | |
| SCHEMBL7793195 | 0.70 | KDM4E (0.44) | FDPSPTPN2PTPN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1328277-B1 | BISPHOSPHONIC COMPOUNDS FOR STRENGTHENING OF CORTICAL BONE | SCHERING AG (DE) | 2007-02-14 | — | — | EP | claimed |
| US-20040014726-A1 | Method for the preparation of a pharmaceutical composition, and its use | SCHERING OY (FI) | 2004-01-22 | — | — | US | claimed |
| EP-0762883-B1 | PYRIDYLBISPHOSPHONATES FOR USE AS A THERAPEUTICAL AGENT | LEIRAS OY (FI) | 2001-11-14 | — | — | EP | claimed |
| EP-0762883-A1 | PYRIDYLBISPHOSPHONATES FOR USE AS A THERAPEUTICAL AGENT | LEIRAS OY (FI) | 1997-03-19 | — | — | EP | claimed |
| WO-1995033466-A1 | PYRIDYLBISPHOSPHONATES FOR USE AS A THERAPEUTICAL AGENT | LEIRAS OY (FI) | 1995-12-14 | — | — | WO | claimed |
| EP-1328277-B1 | BISPHOSPHONIC COMPOUNDS FOR STRENGTHENING OF CORTICAL BONE | SCHERING AG (DE) | 2007-02-14 | — | — | EP | disclosed |
| US-20040014726-A1 | Method for the preparation of a pharmaceutical composition, and its use | SCHERING OY (FI) | 2004-01-22 | — | — | US | disclosed |
| EP-1328277-A1 | METHOD FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION, AND ITS USE | Schering Oy (FI) | 2003-07-23 | — | — | EP | disclosed |
| WO-2002034269-A1 | METHOD FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION, AND ITS USE | SCHERING OY (FI) | 2002-05-02 | — | — | WO | disclosed |
| EP-0762883-B1 | PYRIDYLBISPHOSPHONATES FOR USE AS A THERAPEUTICAL AGENT | LEIRAS OY (FI) | 2001-11-14 | — | — | EP | disclosed |
| US-6083938-A | TREATING BONE DISEASES SELECTED FROM THE GROUP CONSISTING OF OSTEOLYTIC BONE DISEASES DUE TO MALIGNANCY, PAGET'S DISEASE AND PRIMARY AND SECONDARY OSTEOPOROSIS | LEIRAS OY (FI) | 2000-07-04 | — | — | US | disclosed |
| EP-0563107-B1 | NOVEL METHYLENEBISPHOSPHONIC ACID DERIVATIVES | LEIRAS OY (FI) | 2000-05-03 | — | — | EP | disclosed |
| US-5866556-A | BONE DISORDERS | LEIRAS OY (FI) | 1999-02-02 | — | — | US | disclosed |
| US-5393748-A | Treating bone disorders, Paget* s disease, calcium metabolism disorders | LEIRAS OY (FI) | 1995-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014726-A1 | Method for the preparation of a pharmaceutical composition, and its use | HRH3, ARG1, HRH4 | FDPS 2403/4885PTPN2 2557/4885PTPN1 1900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.